Skip to main content
. Author manuscript; available in PMC: 2008 Oct 8.
Published in final edited form as: Cancer Cell. 2007 May;11(5):395–406. doi: 10.1016/j.ccr.2007.02.025

Figure 1. PPARγ Activation Enhances Carboplatin Growth Inhibition in A549 Lung Adenocarcinoma Cells.

Figure 1

(A) A549 cells treated with 0.5 μM of rosiglitazone and indicated doses of carboplatin alone or in combination.

(B) A549 cells were treated with 1 μm rosiglitazone, 250 nM GW1929, or carboplatin, alone or in combination.

(C) A549 cells were treated with 0.5 μM rosiglitazone alone or in combination with 250 nM GW9662, with and without carboplatin.

(D) Interaction of rosiglitazone with different platinum-based drugs. A549 cells treated with 0.5 μM rosiglitazone, 10 μM carboplatin, 1 μM cisplatin, or 1 μM oxaliplatin alone or in combination. Cell number was determined after 7–10 days and expressed as a percent of control cells. Representative experiments, n = 3, mean ± SD. *p < 0.05, **p < 0.01.